EUVIMEDEUVIMED entdecken
Crossref

Association of baseline anti-Ro52 seropositivity with connective tissue disease development following interferon-α therapy in patients with chronic hepatitis B

Yongxin Ma, Hongyan Qian, Caixia Zheng, Chaoqiong Deng, Xiaomei Liu, Xiulan Xue, Zhibin Li, Guixiu Shi, Yuechi Sun

Clinical Rheumatology · 2026

DOI: 10.1007/s10067-026-08317-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Yongxin Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen…. Hauptthemen laut MEDLINE: Interferon-alpha, Hepatitis B, Chronic, Antiviral Agents, Connective Tissue Diseases. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, Xiamen Municipal Bureau of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this study was to investigate whether baseline anti-Ro52 positivity was associated with the connective tissue disease (CTD) development in patients with chronic hepatitis B (CHB) receiving interferon-α (IFN-α) therapy.

Design

We conducted a retrospective cohort study of patients with CHB who initiated IFN-α therapy between January 2021 and December 2023. Associations between baseline anti-Ro52 positivity and CTD development were evaluated using Kaplan–Meier analysis and Cox proportional hazards models.

Results

A total of 1178 patients were included. Nine percent of CHB patients were positive for anti-Ro52 before IFN-α therapy and that 19.02% were positive after IFN-α therapy. There were 120 newly developed CTDs (120/1178, 10.19%) during IFN-α therapy, most of which were undifferentiated CTDs (UCTDs) (110/120, 91.67%). No statistically significant difference in CTD incidence was observed between the anti-Ro52 − and anti-Ro52 + groups (9.79% vs. 14.15%, P = 0.176). Multivariate Cox regression analyses revealed that female sex (HR = 1.53; 95% CI: 1.01–2.33; P = 0.045), IFN-α therapy duration ≥ 12 months (HR = 2.41; 95% CI: 1.62–3.59; P < 0.001), anti-Ro60 positivity (HR = 3.82; 95% CI: 1.82–8.03; P < 0.001), and Scl-70 positivity (HR = 5.65; 95% CI: 1.37–23.36; P = 0.017) were risk factors for CTD development in CHB patients after IFN-α therapy, whereas IFN-α therapy combined with NA therapy was associated with a decreased risk (HR = 0.56; 95% CI: 0.33–0.95; P = 0.031).

Conclusion

Baseline anti-Ro52 positivity was not significantly associated with CTD development in patients with CHB receiving IFN-α therapy. Instead, CTD development appears to be associated with multiple clinical and serological characteristics, including female sex, prolonged IFN-α therapy, baseline anti-Ro60 positivity, and anti-Scl-70 positivity. Prospective studies with larger cohorts and longer follow-up are warranted to confirm these observations. Key Points • Anti-Ro52 positivity is common in CHB patients and significantly increased after IFN-α therapy. • Baseline anti-Ro52 positivity alone does not appear to be associated with subsequent CTD development in patients with CHB receiving IFN-α therapy. • Female sex, a duration of IFN-α therapy longer than 12 months, anti-Ro60 positivity, and anti-Scl70 positivity were associated with CTD development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon-alphaHepatitis B, ChronicAntiviral AgentsConnective Tissue DiseasesAntibodies, AntinuclearRibonucleoproteinsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedSS-A AntigenProportional Hazards Models

Stichwörter der Autor:innen

Anti-Ro52Chronic hepatitis B virusConnective tissue diseasesImmunityInterferon-alpha

Substanzen

Interferon-alphaAntiviral AgentsAntibodies, AntinuclearSS-A AntigenRibonucleoproteins

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, 361000, China.
  • Xiamen Municipal Clinical Research Center for Immune Diseases, Xiamen, 361000, China.
  • Xiamen Key Laboratory of Rheumatology and Clinical Immunology, Xiamen, 361000, China.
  • Department of Infectious Diseases, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, 361000, China.
  • Department of Infectious Diseases, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, 361000, China. xuexiulan2003@126.com.
  • Epidemiology Research Unit, Center of Translational Medical Research, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, 361000, China. zhibinli33@163.com.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Fujian Province
  • Xiamen Municipal Bureau of Science and Technology

Zitieren

APA

Ma, Y., Qian, H., Zheng, C., Deng, C., Liu, X., Xue, X., Li, Z., Shi, G., & Sun, Y. (2026). Association of baseline anti-Ro52 seropositivity with connective tissue disease development following interferon-α therapy in patients with chronic hepatitis B. Clinical Rheumatology. https://doi.org/10.1007/s10067-026-08317-2

Vancouver

Ma Y, Qian H, Zheng C, Deng C, Liu X, Xue X, et al. Association of baseline anti-Ro52 seropositivity with connective tissue disease development following interferon-α therapy in patients with chronic hepatitis B. Clinical Rheumatology. 2026. doi:10.1007/s10067-026-08317-2

BibTeX
@article{Ma2026,
  author = {Ma, Yongxin and Qian, Hongyan and Zheng, Caixia and Deng, Chaoqiong and Liu, Xiaomei and Xue, Xiulan and Li, Zhibin and Shi, Guixiu and Sun, Yuechi},
  title = {Association of baseline anti-Ro52 seropositivity with connective tissue disease development following interferon-α therapy in patients with chronic hepatitis B},
  journal = {Clinical Rheumatology},
  year = {2026},
  doi = {10.1007/s10067-026-08317-2}
}
Kostenlos starten →